Navigation Links
Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
Date:12/8/2009

eristic of the drug to iron complex formation, confirming the expected 1:3 Fe(II)-drug ratio for both doxorubicin and mitoxantrone. In contrast, no spectrophotometric changes were observed with iron added to pixantrone, clearly demonstrating that pixantrone does not bind iron. In vitro studies using H2C9 rat myocardial cells indicate that pixantrone (ID50 >50 ug/ml) is far less toxic than doxorubicin (ID50= 1 ug/ml). Moreover, pixantrone does not induce significant reactive oxygen species (ROS) production in the H2C9 cells compared to doxorubicin.

About Pixantrone

Pixantrone (BBR 2778), is a novel topoisomerase II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class. Pixantrone has been granted fast track status designation.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, '/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BD Ranked in the Top 100 Greenest Big Companies by Newsweek; Named Again to Dow Jones Sustainability World and North America Indexes
2. US Oncology, Inc. to Exhibit iKnowMed(TM) at the 2009 ASCO EHR Symposium: Harnessing the EHR: From Incentives to Sustainability
3. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
4. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
5. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
6. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
9. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... CORALVILLE, Iowa , Sept. 23, 2014 /PRNewswire/ ... in the discovery and development of proprietary new ... received a No Objection Letter (NOL) from Health ... Canada for its lead product candidate ... hydrocodone prodrug in development for acute moderate to ...
(Date:9/23/2014)... 23, 2014 According to ... Product (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application ... - Global Forecasts to 2019", published by MarketsandMarkets, studies ... period of 2014 to 2019. The market is ... CAGR of 9.6% from 2014 to 2019. ...
(Date:9/23/2014)... 23, 2014  Medela announced today that it has ... assigning Medela as the exclusive distributor of the ABC ... Medela Enteral Feeding Pump. Through this agreement, Medela will ... and healthcare professionals by offering a comprehensive set of ... Pump is integral to the delivery of human milk ...
Breaking Medicine Technology:KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 2
... 14, 2011 Novocure, a commercial stage private ... former senior OSI Pharmaceuticals executives to its Global ... for bringing the company,s new tumor treating fields ... Peter M. Melnyk has joined Novocure as ...
...  SRI International has been awarded a contract worth up ... Institute of Allergy and Infectious Diseases (NIAID), part of ... will allow SRI to continue a program that supports ... the translation of basic research into clinical applications. Since ...
Cached Medicine Technology:Novocure Adds Three Senior Oncology Executives to its Global Management Team 2Novocure Adds Three Senior Oncology Executives to its Global Management Team 3Novocure Adds Three Senior Oncology Executives to its Global Management Team 4SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases 2SRI International Awarded Contract Worth Up to $100M From National Institute of Allergy and Infectious Diseases 3
(Date:9/23/2014)... Genomic medicine is rapidly developing, bringing with its ... and optimize prevention and treatment interventions. Genetic ... immunodeficiency virus (HIV) and hepatitis c virus (HPC), ... be used to screen for an individual,s susceptibility ... treatments for addiction. , While there appear to ...
(Date:9/23/2014)... 23, 2014 What information do ... National Quality Forum (NQF) released a report ( ... and an infographic ( http://bit.ly/1tX3lzA ) resulting from ... healthcare, how patients define affordability, and what information ... the best possible healthcare at the lowest possible ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 What: ... Manhattan’s Upper West Side that embodies the inclusion ... Eden: Christians, Scripture and the Ecological Crisis, a ... B. Rhodes Professor Emerita of Old Testament at ... for ancient wisdom that lends insight into current ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- The number of ... drugs is growing, so doctors need to be ... Drug Administration warned Tuesday. In a statement, ... that it has launched a program to educate ... about proper drug purchasing procedures. The program aims ...
(Date:9/23/2014)... obese as teenagers could grow up to earn up ... weight. So says Petter Lundborg of Lund University, Paul ... University and Lund University, all in Sweden. The team ... the United States, and the results are published in ... analyzed large-scale data of 145,193 Swedish-born brothers who enlisted ...
Breaking Medicine News(10 mins):Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2Health News:Note to young men: Fat doesn't pay 2
... A path breaking research published today seems to have ... be able to manufacture their own sperms. Lesbian couples// ... ,Researchers have applied for permission to generate synthetic ... this move will be ethical is a question that ...
... the key to not only stopping heart attacks in ... Researchers at Mount Sinai School of Medicine have shown ... novel contrast agent know as N1177 can detect dangerous, ... findings may help physicians diagnosis a heart attack before ...
... Alirajpur in Jhabua district, beat his wife to death. Reason? ... another young man killed his brother with an arrow when ... owned by him. ,Often the reasons for murders ... entering the neighbour's territory or someone's refusal to lend a ...
... - If you are obese, blame it on your gene. A ... called FTO portray mutation in both their copies, then such people ... people who possess normal copies of the gene. ,Researchers ... of what is happening, this research could give us an answer ...
... M.D., director of the Yale Child Study Center and ... discuss the expansion of the Center’s specialty clinical services ... at Greenwich Library, 101 W. Putnam Ave., Greenwich. ... new clinical services, which will also benefit clients from ...
... Northeastern states in the US are stepping up their efforts ... mercury emissions.// ,Throughout the Northeast, mercury contamination ... that occurs naturally. , It is released ... generating plants. ,Smokestack emissions drift across state ...
Cached Medicine News:Health News:CT Imaging With Novel Contrast Agent May Predict Heart Attack in Waiting 2Health News:Efforts Underway to Fight Alcoholism Among Tribals 2Health News:Efforts Underway to Fight Alcoholism Among Tribals 3Health News:Efforts Underway to Fight Alcoholism Among Tribals 4Health News:US States Get Ready to Fight Mercury Pollution 2